Supernus Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Supernus Pharmaceuticals Inc in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Supernus Pharmaceuticals Inc Strategy Report

  • Understand Supernus Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Supernus Pharmaceuticals Inc: Overview

Select Item

Related keylists

Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-817, and SPN-820. The company's technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company majority customers include pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.

 Gain a 360-degree view of Supernus Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Supernus Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 9715 Key West Avenue, Rockville, Maryland, 20850
Website www.supernus.com
Telephone 1 301 8382500
No of Employees 652
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange SUPN (NASD)
Revenue (2022) $607.5M -8.9% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -97.8% (2022 vs 2021)
Market Cap* $1.7B
Net Profit Margin (2022) XYZ -97.6% (2022 vs 2021)
* As of and is in US$
View Supernus Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Supernus Pharmaceuticals Inc premium industry data and analytics

100+

Clinical Trials

Determine Supernus Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Catalyst Calendar

Proactively evaluate Supernus Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Supernus Pharmaceuticals Inc’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of Supernus Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

12+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Supernus Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

10+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

8

Marketed Drugs

Understand Supernus Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Supernus Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Trokendi XR: Supernus
Migraine XADAGO
Epilepsy MYOBLOC
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Supernus Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Supernus Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Others In November, the company announced that the U.S. Food and Drug Administration acknowledged the resubmission of the new drug application for its apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson’s disease (PD).
2023 Others In October, the company resubmitted its New Drug Application for its apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson’s disease.
2023 Contracts/Agreements In February, the company entered into an agreement with UBS Bank USA providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Supernus Pharmaceuticals Inc Glenmark Pharmaceuticals Ltd Vanda Pharmaceuticals Inc Acorda Therapeutics Inc Sage Therapeutics Inc
Headquarters United States of America India United States of America United States of America United States of America
City Rockville Mumbai Washington Pearl River Cambridge
State/Province Maryland Maharashtra WashingtonD.C. New York Massachusetts
No. of Employees 652 15,556 203 102 487
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Charles W. Newhall, III Chairman Executive Board 2016 78
Jack A. Khattar President; Secretary; Chief Executive Officer; Director Executive Board 2005 61
Timothy C. Dec Chief Financial Officer; Senior Vice President Senior Management 2021 65
Jonathan Rubin, MD Chief Medical Officer; Senior Vice President - Research and Development Senior Management 2021 61
Padmanabh P. Bhatt, Ph.D. Senior Vice President - Intellectual Property; Chief Scientific Officer Senior Management 2012 65
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Supernus Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Supernus Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward